Menu
Recruiting NCT06507930

The COMPASSION Study

No phase Interventional Breast Cancer Metastatic Breast Cancer Advanced Breast Cancer Unresectable Breast Carcinoma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Telehealth Hospice Visits.
Who it may be relevant to
Registry conditions: Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Breast Carcinoma. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

The COMPASSION Study: Applying Telehealth to Innovate and Strengthen Connections for Patients With Metastatic Breast Cancer Receiving Hospice Care

Overview

The aim of this research study is to better understand the in-home hospice experience for participants, caregivers, hospice nurses, and oncology providers by conducting telehealth check-ins between participants and caregivers and oncology care teams.

Detailed description

The aim of this research study is to better understand the in-home hospice experience for participants, caregivers, hospice nurses, and oncology providers by conducting telehealth check-ins between participants and caregivers and oncology care teams.

Study procedures include giving verbal consent to participate and a one-time survey delivered by email or phone call.

About 200 people, which includes 50 participants, 50 caregivers, 50 hospice nurses, and about 50 oncology providers, are expected to participate in this research study.

Interventions

  • Other Telehealth Hospice Visits
    Telehealth check-in appointments with oncology care team, MD, PA, NP, or hospice nurse, via HIPAA compliant telehealth platform, Zoom, or by phone call.

Primary outcome measures

  • Proportion of Participant Intervention Completion [Time frame: Up to 4 weeks]

Eligibility criteria

Inclusion criteria

  • Patient of any gender with unresectable locally advanced or metastatic breast cancer
  • Eligible for in-home hospice services and referred by DFCI clinical team to in-home hospice </= 1 week before enrollment
  • Ability to conduct video or phone check-ins, even if assistance required.
  • Able to provide verbal consent with a willingness to take a survey at 4-6 weeks, if medically able
  • Hospice setting is within Massachusetts
  • Non-English language allowed but interpreter services must be present at each meeting and will be coordinated by scheduling team
  • Willingness to provide a caregiver/loved one's contact information for survey contact at 4 weeks after enrollment

Exclusion criteria

  • Unable to provide verbal consent
  • Hospice care planned outside of a home setting (note: if participants start out in a home hospice setting but later transition their hospice care to an inpatient setting, enrollment is allowed as long as they started in a home setting)
  • Hospice setting outside of Massachusetts
  • Individuals who are under the age of 18, as this is not a project focused on pediatric patients.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Non-randomized
Model
Sequential
Masking
Open label
Primary purpose
Health services research

Study locations

United States · 1 center
  • Dana-Farber Cancer Institute — Boston

Identifiers

NCT: NCT06507930 · 24-142

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗